ADMS Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief Executive, is scheduled to present at the following investor conference:

• Bank of America Merrill Lynch (BAML) 2019 Health Care Conference on Wednesday, May 15 at 1:40 p.m. EDT (10:40 a.m. PDT)

The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contact:

Investors: Peter VozzoManaging Director, Westwicke443-213-0505peter.vozzo@westwicke.com

Media: Sarah MathiesonVice President of Corporate Communications510-450-3528smathieson@adamaspharma.com